Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany

被引:26
作者
Dall, Peter [1 ,2 ]
Lenzen, Gertrud
Goehler, Thomas [3 ]
Lerchenmueller, Christian
Feisel-Schwickardi, Gabriele [4 ,5 ]
Koch, Thorsten [6 ]
Eggert, Jochen
Heilmann, Volker
Schindler, Christof
Wilke, Jochen
Tesch, Hans [7 ]
Selbach, Johannes
Wohlfarth, Tim [8 ]
Eustermann, Heidi [9 ]
Hinke, Axel [9 ]
机构
[1] Klinikum Luneburg, Dept Obstet & Gynaecol, Luneburg, Germany
[2] Klinikum Luneburg, Breast Canc Ctr, Luneburg, Germany
[3] Onkozentrum Dresden Freiberg, Dresden, Germany
[4] Klinikum Kassel, Dept Obstet & Gynaecol, Kassel, Germany
[5] Klinikum Kassel, Breast Canc Ctr, Kassel, Germany
[6] Klinikum Nurnberg, Breast Ctr, Nurnberg, Germany
[7] Onkol Bethanien, Frankfurt, Germany
[8] Roche Pharma AG, Grenzach Wyhlen, Germany
[9] WiSP Res Inst, Langenfeld, Germany
关键词
Early breast cancer; Elderly patients; Her2; overexpression; Trastuzumab; Non-interventional study; RANDOMIZED CONTROLLED-TRIAL; PLUS ADJUVANT CHEMOTHERAPY; FOLLOW-UP; GERIATRIC ONCOLOGY; OLDER WOMEN; NSABP B-31; THERAPY; METAANALYSIS;
D O I
10.1016/j.jgo.2015.06.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In elderly patients with HER2-positive breast cancer, few data on efficacy and toxicity of adjuvant trastuzumab treatment exists since older patients were in general excluded from large randomized studies. This prospective observational study aimed to confirm the beneficial findings from pivotal trials in age cohorts >= 65 years. Materials and Methods: There were no restrictions for recruitment with respect to age or concomitant/sequential adjuvant medication. Long-term relapse/survival status of the patients was assessed once a year. Results: Among the 3940 evaluable patients enrolled between 2006 and 2012 at 339 institutions, 507 were aged between 65 and 69 years, with another 507 patients >= 70 years. Elderly patients suffered from significantly more advanced primary tumors. Preceding or concomitant chemotherapy showed decreasing aggressiveness with patient's age. Trastuzumab treatment was stopped prematurely in only 11% of the elderly, but more often than in younger patients (p = 0.0008). With 453 events hitherto reported, elderly patients did not exhibit an inferior relapse-free survival when adjusted for other relevant prognostic factors (hazard ratio: 1.01 per year; p = 0.24). Three-year overall survival was significantly lower in the population older than 64 years than in younger patients (94.2% vs. 96.8%, p = 0.0011). Conclusions: To our knowledge, our population of elderly patients treated with adjuvant trastuzumab is the largest analyzed so far. The beneficial long-term results were comparable to those in the younger cohorts. Although the risk of cardiotoxicity increased significantly with age, it also remained manageable in older patients. Thus, chronological age alone should not preclude HER2 antibody treatment. (C) 2015 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:462 / 469
页数:8
相关论文
共 31 条
[1]   The Elderly: Geriatric oncology finally deserving adequate attention [J].
Aapro, M. ;
Johnson, C. D. .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (16) :2312-2314
[2]   Management of primary and advanced breast cancer in older unfit patients (medical treatment) [J].
Aapro, M. ;
Monfardini, Silvio ;
Jirillo, Antonio ;
Basso, Umberto .
CANCER TREATMENT REVIEWS, 2009, 35 (06) :503-508
[3]   Trastuzumab in small tumours and in elderly women [J].
Albanell, Joan ;
Ciruelos, Eva M. ;
Lluch, Ana ;
Munoz, Montserrat ;
Rodriguez, Cesar A. .
CANCER TREATMENT REVIEWS, 2014, 40 (01) :41-47
[4]   Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer [J].
Barcenas, Carlos H. ;
Niu, Jiangong ;
Zhang, Ning ;
Zhang, Yufeng ;
Buchholz, Thomas A. ;
Elting, Linda S. ;
Hortobagyi, Gabriel N. ;
Smith, Benjamin D. ;
Giordano, Sharon H. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) :2010-U48
[5]   Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials [J].
Brollo, Janaina ;
Curigliano, Giuseppe ;
Disalvatore, Davide ;
Marrone, Bianca Fontana ;
Criscitiello, Carmen ;
Bagnardi, Vincenzo ;
Kneubil, Maximiliano Cassilha ;
Fumagalli, Luca ;
Locatelli, Marzia ;
Manunta, Silvia ;
Goldhirsch, Aron .
CANCER TREATMENT REVIEWS, 2013, 39 (01) :44-50
[6]   Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer [J].
Chen, Jersey ;
Long, Jessica B. ;
Hurria, Arti ;
Owusu, Cynthia ;
Steingart, Richard M. ;
Gross, Cary P. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (24) :2504-2512
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]   Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials [J].
Dahabreh, Issa J. ;
Linardou, Helen ;
Siannis, Fotios ;
Fountzilas, George ;
Murray, Samuel .
ONCOLOGIST, 2008, 13 (06) :620-630
[9]   Tumor characteristics and clinical outcome of elderly women with breast cancer [J].
Diab, SG ;
Elledge, RM ;
Clark, GM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (07) :550-556
[10]   Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient [J].
Freedman, Rachel A. ;
Muss, Hyman B. .
JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) :2-7